Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) EBITDA Margin (2018 - 2026)

Catalyst Pharmaceuticals filings provide 9 years of EBITDA Margin readings, the most recent being 42.67% for Q1 2026.

  • On a quarterly basis, EBITDA Margin rose 261.0% to 42.67% in Q1 2026 year-over-year; TTM through Mar 2026 was 37.08%, a 17.0% increase, with the full-year FY2025 number at 36.38%, up 304.0% from a year prior.
  • EBITDA Margin hit 42.67% in Q1 2026 for Catalyst Pharmaceuticals, up from 34.53% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 42.67% in Q1 2026 to a low of 29.96% in Q3 2023.
  • Median EBITDA Margin over the past 5 years was 35.55% (2025), compared with a mean of 32.13%.
  • Biggest five-year swings in EBITDA Margin: plummeted -6998bps in 2023 and later skyrocketed 6406bps in 2024.
  • Catalyst Pharmaceuticals' EBITDA Margin stood at 41.91% in 2022, then decreased by -25bps to 31.51% in 2023, then rose by 25bps to 39.49% in 2024, then decreased by -13bps to 34.53% in 2025, then grew by 24bps to 42.67% in 2026.
  • The last three reported values for EBITDA Margin were 42.67% (Q1 2026), 34.53% (Q4 2025), and 35.55% (Q3 2025) per Business Quant data.